ライフサイエンスコーパス: lymphatic filariasis

1 c expansion in a chronic helminth infection (lymphatic filariasis).

2 sport in Brugia malayi, a causative agent of lymphatic filariasis.

3 s the potential to accelerate elimination of lymphatic filariasis.

4 parasitic diseases like river blindness and lymphatic filariasis.

5 a bancrofti, one of the nematodes that cause lymphatic filariasis.

6 and Mansonia africana, which are vectors of lymphatic filariasis.

7 is virus, as well as of nematodes that cause lymphatic filariasis.

8 hanism underlying T cell immune tolerance in lymphatic filariasis.

9 igen-specific T-cell response seen in patent lymphatic filariasis.

10 ation of the vector-borne parasitic disease, lymphatic filariasis.

11 d from 67 North Americans with no history of lymphatic filariasis.

12 s into the ecology and pathogenesis of human lymphatic filariasis.

13 mmatory diseases such as river blindness and lymphatic filariasis.

14 evaluation of programs aimed at eliminating lymphatic filariasis.

15 de Brugia malayi, a causative agent of human lymphatic filariasis.

16 cy of IFN-gamma- and IL-4-producing cells in lymphatic filariasis.

17 malayi, one of the causative agents of human lymphatic filariasis.

18 closely associated with cytokine patterns in lymphatic filariasis.

19 llenge the concept of protective immunity in lymphatic filariasis, 19 adult residents of a Wuchereria

20 n settings with a low baseline prevalence of lymphatic filariasis (5%), the triple-drug regimen reduc

21 sitic diseases including river blindness and lymphatic filariasis affect hundreds of millions of peop

22 which is associated with disease in chronic lymphatic filariasis and could potentially have an impor

23 Lymphatic filariasis and intestinal helminth infections

24 Lymphatic filariasis and loiasis are major human disease

25 ases caused by filarial nematodes, including lymphatic filariasis and onchocerciasis (river blindness

26 Lymphatic filariasis and onchocerciasis are parasitic he

27 Lymphatic filariasis and onchocerciasis are parasitic he

28 ach to larger-scale ivermectin treatment for lymphatic filariasis and onchocerciasis in areas where L

29 cy of minocycline treatment regimens against lymphatic filariasis and onchocerciasis.

30 ld be used in the global effort to eliminate lymphatic filariasis and possibly for the control of oth

31 mass drug administration for elimination of lymphatic filariasis and soil-transmitted helminth infec

32 ombination to reduce microfilariae in blood (lymphatic filariasis) and skin (onchocerciasis).

33 motherapeutic agents against onchocerciasis, lymphatic filariasis, and heartworm.

34 eases, such as guinea worm, schistosomiasis, lymphatic filariasis, and onchocerciasis, suggests that

35 ydrocoele, lymphoedema, and elephantiasis in lymphatic filariasis, and skin disease and blindness in

36 el of the within-host population dynamics of lymphatic filariasis, and use a simulated goodness-of-fi

37 he impaired Th1 responses observed in patent lymphatic filariasis are associated with decreased expre

38 Global efforts to eliminate lymphatic filariasis are based on the annual mass admini

39 tration campaigns against onchocerciasis and lymphatic filariasis being conducted in areas where Onch

40 ss the potential for school-based control of lymphatic filariasis by investigating the efficacy and t

41 tration with ivermectin plus albendazole for lymphatic filariasis cannot be applied in central Africa

42 However, few such programmes exist for lymphatic filariasis, despite evidence that single-dose

43 provide evidence that protective immunity to lymphatic filariasis does occur and that it is probably

44 Lymphatic filariasis (elephantiasis) is a global public

45 rne diseases, including dengue, malaria, and lymphatic filariasis, exact a devastating toll on global

46 Lymphatic filariasis, frequently caused from Wuchereria

47 s and exciting Global Programme to Eliminate Lymphatic Filariasis (GPELF) is largely based on a strat

48 The Global Program to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with t

49 the Global Programme for the Elimination of Lymphatic Filariasis (GPELF), as interaction dynamics ma

50 o continue the Global Programme to Eliminate Lymphatic Filariasis (GPELF).

51 egy for the elimination of onchocerciasis or lymphatic filariasis has been delayed in Central Africa

52 s potential to accelerate the elimination of lymphatic filariasis if high population coverage of mass

53 s potential to accelerate the elimination of lymphatic filariasis if high population coverage of mass

54 n programs for control of onchocerciasis and lymphatic filariasis in Africa.

55 s administration of albendazole to eliminate lymphatic filariasis in areas where loiasis is co-endemi

56 drug regimen for accelerating elimination of lymphatic filariasis in different epidemiological settin

57 the extracellular parasites responsible for lymphatic filariasis in humans--and the APC with which t

58 Onchocerciasis and lymphatic filariasis in particular are the cause of much

59 ilia (TPE) is a severe asthmatic syndrome of lymphatic filariasis, in which an allergic response is i

60 Lymphatic filariasis is a disease characterized by immun

61 The current global initiative to eliminate lymphatic filariasis is a major renewed commitment to re

62 Lymphatic filariasis is a tropical disease caused by the

63 Patent lymphatic filariasis is characterized by a profound down

64 Patent lymphatic filariasis is characterized by antigen-specifi

65 Patent lymphatic filariasis is characterized by profound Ag-spe

66 population living on a Pacific island where lymphatic filariasis is endemic.

67 gen-specific T-cell unresponsiveness seen in lymphatic filariasis is mediated, in part, by diminished

68 f lymphedema development in individuals with lymphatic filariasis is presently poorly understood.

69 broad spectra of clinical manifestations of lymphatic filariasis is still unknown.

70 Elimination of onchocerciasis and lymphatic filariasis is targeted for 2020.

71 Lymphatic filariasis is targeted for elimination as a pu

72 Lymphatic filariasis (LF) and onchocerciasis are priorit

73 Available treatments for lymphatic filariasis (LF) are limited in their longterm

74 pects of achieving the global elimination of lymphatic filariasis (LF) by 2020.

75 Malaria and lymphatic filariasis (LF) continue to cause a considerab

76 ended as a possible strategy for eliminating lymphatic filariasis (LF) in post-conflict countries suc

77 Lymphatic filariasis (LF) is a major cause of acute and

78 The familial recurrence risk of lymphatic filariasis (LF) is unknown.

79 neglected tropical diseases (NTD), including lymphatic filariasis (LF), scaled up dramatically after

80 e global communities tasked with eliminating lymphatic filariasis (LF), the underlying cause of eleph

81 Using rodent models of lymphatic filariasis (Litomosoides sigmodontis) and nonc

82 Individuals with clinical manifestations of lymphatic filariasis may be currently infected or not.

83 Lymphatic filariasis occurs in endemic pockets.

84 programs, the data available for five NTDs (lymphatic filariasis, onchocerciasis, intestinal helmint

85 ng serum samples from patients with loiasis, lymphatic filariasis, onchocerciasis, mansonellosis, or

86 for the coadministration of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, s

87 Wolbachia from filarial nematodes that cause lymphatic filariasis or onchocerciasis, resulting in blo

88 To test this hypothesis in bancroftian lymphatic filariasis, pedigree data were collected twice

89 , dengue fever and yellow fever viruses, and lymphatic filariasis, respectively.

90 tages of Brugia malayi, a causative agent of lymphatic filariasis, resulting in the identification of

91 Focussing on lymphatic filariasis, schistosomiasis and soil-transmitt

92 cific Th1 and Th2 immune responses occurs in lymphatic filariasis that is governed at the transcripti

93 Human lymphatic filariasis, which afflicts an estimated 120 mi

94 as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public hea

95 e is a safe and well-tolerated treatment for lymphatic filariasis with significant activity against a

96 of Brugia malayi, a causative agent of human lymphatic filariasis, with PBMC of normal individuals.

97 doxycycline treatment on the major cause of lymphatic filariasis, Wuchereria bancrofti.